Type Condition

Anniston, AL

219 Clinical Trials near Anniston, AL

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Novel Antibody Prophylaxis for COVID-19

Birmingham, Alabama
This trial is testing a new drug, AZD3152, and a combination drug to see if they can prevent COVID-19. It focuses on people with weak immune systems who might not respond well to vaccines, as well as healthy adults. The drug works by blocking the virus from entering cells.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:12+

3882 Participants Needed

Umbilical Cord Patch (TTAX01) for Diabetic Foot Ulcers

Guntersville, Alabama
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

220 Participants Needed

Lorundrostat for High Blood Pressure

Alexander City, Alabama
This trial tests lorundrostat, a medication that lowers blood pressure by blocking an enzyme involved in hormone production. It targets patients with high blood pressure not controlled by 2 to 5 other medications.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:19+
Sex:Male

1083 Participants Needed

Vericiguat for Heart Failure

Alexander City, Alabama
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

6105 Participants Needed

DOR/ISL for HIV

Birmingham, Alabama
This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL \[also known as MK-8591A\]) in treatment-naïve participants with human immunodeficiency virus type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

599 Participants Needed

TTAX03 Injection for Knee Osteoarthritis

Birmingham, Alabama
This trial tests if a single injection of TTAX03 in saltwater can improve knee conditions better than just saltwater. It targets patients needing knee injections and checks their response over a few months.

Trial Details

Trial Status:Active Not Recruiting
Age:35 - 85

90 Participants Needed

Navitoclax + Ruxolitinib for Myelofibrosis

Birmingham, Alabama
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

191 Participants Needed

CSF Drain Placement for Aortic Aneurysm

Birmingham, Alabama
This trial aims to see if using CSF drains before surgery can prevent spinal cord injury in patients having endovascular thoracoabdominal aneurysm repair. The study focuses on patients at risk of spinal cord injury due to reduced blood flow during the procedure. CSF drains help by lowering pressure around the spinal cord, improving blood flow and potentially preventing injury. CSF drainage has been used to protect the spinal cord during thoracic and thoracoabdominal aortic surgeries by reducing the risk of paraplegia.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

20 Participants Needed

Advanced Pneumatic Compression Device for Lymphedema

Birmingham, Alabama
This trial compares the effectiveness of an air pressure device (APCD) to standard treatment in reducing swelling and improving quality of life for head and neck cancer survivors. The device works by gently massaging the swollen areas to help move excess fluid out of the tissues.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

250 Participants Needed

Enhanced Cluster Detection Methods for Outbreak Control

Rome, Georgia
Despite the critical importance of identifying hospital-associated outbreaks as early as possible in order to limit their spread, there are currently no standardized methods for cluster detection. The CLUSTER Trial (Cluster Linkage Using Statistics to Trigger and Evaluate Response) will assess whether a statistically-based automated cluster detection method coupled with a robust response protocol will enable rapid containment of hospital clusters as measured by a reduction in cluster size and duration as compared to routine hospital cluster detection methods coupled with the same response protocol. Note: that enrolled "subjects" represents 82 individual HCA Healthcare hospitals that have been randomized
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

82 Participants Needed

Smart Prompt System vs Routine Care for Urinary Tract Infection

Rome, Georgia
The INSPIRE-ASP UTI trial is a cluster-randomized controlled trial of HCA hospitals comparing routine empiric antibiotic stewardship practices with real-time precision medicine computerized physician order entry smart prompts providing the probability that a non-critically ill adult admitted with UTI is infected with a resistant pathogen. Note: that enrolled "subjects" represents 59 individual HCA hospitals that have been randomized.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

59 Participants Needed

Smart Antibiotic Use Prompt for Pneumonia

Rome, Georgia
The INSPIRE-ASP PNA trial is a cluster-randomized controlled trial of HCA hospitals comparing routine empiric antibiotic stewardship practices with real-time precision medicine computerized physician order entry smart prompts providing the probability that a non-critically ill adult admitted with PNA is infected with a resistant pathogen. Note: that enrolled "subjects" represents 59 individual HCA hospitals that have been randomized.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

59 Participants Needed

Serplulimab + Chemotherapy for Small Cell Lung Cancer

Birmingham, Alabama
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

200 Participants Needed

Active on Power

Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)

Birmingham, Alabama
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+

249 Participants Needed

Active on Power

SEP-363856 for Major Depressive Disorder

Birmingham, Alabama
A Phase 2/3 Trial is designed to evaluate SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65

900 Participants Needed

Active on Power

CYB003 for Depression

Birmingham, Alabama
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3

330 Participants Needed

Active on Power

ABX-002-2001 for Depression

Birmingham, Alabama
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.  This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening (approximately 35 days)  2. Treatment period (42 days)  3. Follow-up (2 weeks post treatment)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

230 Participants Needed

Amlitelimab for Atopic Dermatitis (SHORE)

Birmingham, Alabama
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+

643 Participants Needed

KarXT for Alzheimer's-Associated Psychosis

Homewood, Alabama
This trial is testing KarXT, a medication, to see if it can prevent psychotic symptoms from returning in people with Alzheimer's Disease. It works by balancing brain chemicals that cause hallucinations and delusions. KarXT has shown positive results in reducing symptoms of schizophrenia.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:55 - 90

380 Participants Needed

Donanemab for Alzheimer's Disease

Homewood, Alabama
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:65 - 80

2996 Participants Needed

Why Other Patients Applied

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

Sacubitril-Valsartan for High Blood Pressure

Birmingham, Alabama
Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death. Natriuretic Peptides (NPs) are hormones produced by the heart which directly regulate BP by causing dilation of blood vessels and by removing sodium and water from the body. NPs have a 24-hour day-night rhythm and this controls the day-night rhythm of BP as well. The NP-BP rhythm relationship is broken down in obese individuals. Obese individuals also have lower circulating NP levels. Lower circulating levels of NPs and elevated renin hormone (a part of the Renin-Angiotensin-Aldosterone System \[RAAS\]) at nighttime may contribute to the high nocturnal blood pressure in obese individuals which puts them at a higher risk of developing CV events. This current study seeks to determine the biological implications of chronopharmacology for synchronizing NP-RAAS-based blood pressure therapy with the physiological diurnal rhythms to restore the normal diurnal rhythm of blood pressure in obese individuals.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

160 Participants Needed

Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis

Birmingham, Alabama
This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

924 Participants Needed

Recombinant Factor VIIa for Hemorrhagic Stroke

Birmingham, Alabama
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

350 Participants Needed

Psilocybin for Depression

Birmingham, Alabama
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3

240 Participants Needed

Valproic Acid for Traumatic Brain Injury

Birmingham, Alabama
The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal saline 2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65

432 Participants Needed

Gemcitabine + BCG for Bladder Cancer

Birmingham, Alabama
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Intravesical BCG is a solution containing the live BCG bacteria that is placed in the bladder via a catheter (intravesical). When the solution comes into direct contact with the bladder wall, it stimulates the body's immune system which kills tumor cells. Giving gemcitabine with intravesical BCG may kill more tumor cells in patients with recurrent non-muscle invasive bladder cancer.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

330 Participants Needed

Aspirin for Preterm Birth

Birmingham, Alabama
This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:14+
Sex:Female

1800 Participants Needed

Oral Tranexamic Acid for Shoulder Replacement Surgery

Birmingham, Alabama
The purpose of this clinical trial is to evaluate the short-term clinical outcomes of patients undergoing total shoulder arthroplasty who receive an extended postoperative course of oral tranexamic acid
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3

60 Participants Needed

Daraxonrasib for Non-Small Cell Lung Cancer

Birmingham, Alabama
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

420 Participants Needed

Pelacarsen for Cardiovascular Disease

Birmingham, Alabama
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

600 Participants Needed

1...678

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Anniston, AL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Anniston, AL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Anniston, AL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Anniston, AL is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Anniston, AL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Anniston, AL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Anniston, AL?

Most recently, we added Psilocybin for Depression, Valproic Acid for Traumatic Brain Injury and Oral Tranexamic Acid for Shoulder Replacement Surgery to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Alabama

Anxiety Clinical Trials in Alabama

Schizophrenia Clinical Trials in Alabama

ADHD Clinical Trials in Alabama

Bipolar Disorder Clinical Trials in Alabama

Multiple Sclerosis Clinical Trials in Alabama

Autism Clinical Trials in Alabama

Treatment Resistant Depression Clinical Trials in Alabama

Borderline Personality Disorder Clinical Trials in Alabama

Social Anxiety Disorder Clinical Trials in Alabama

Parkinson's Disease Clinical Trials in Alabama

Alzheimer's Disease Clinical Trials in Alabama

By Location

Clinical Trials near Birmingham, AL

Clinical Trials near Mobile, AL

Clinical Trials near Huntsville, AL

Clinical Trials near Anniston, AL

Clinical Trials near Dothan, AL

Clinical Trials near Montgomery, AL

Clinical Trials near Tuscaloosa, AL

Clinical Trials near Homewood, AL

Clinical Trials near Cullman, AL

Clinical Trials near Muscle Shoals, AL

Clinical Trials near Jasper, AL

Clinical Trials near Sheffield, AL

Other People Viewed

By Subject

188 Clinical Trials near Fairhope, AL

216 Clinical Trials near Alabaster, AL

30 Depression Trials near Birmingham, AL

210 Clinical Trials near Alexander City, AL

215 Clinical Trials near Haleyville, AL

24 Arthritis Trials near Birmingham, AL

197 Clinical Trials near Huntsville, AL

219 Clinical Trials near Glen Burnie, MD

197 Clinical Trials near Elwood, IN

Top Clinical Trials near Alabama

Top Al Amyloidosis Clinical Trials

Top Clinical Trials near Florence, AL

By Trial

BI 690517 + Empagliflozin for Heart Failure

Letrozole + Abemaciclib vs Pembrolizumab for Endometrial Cancer

Radiation Therapy for Prostate Cancer

Hormone Therapy + Chemotherapy for Breast Cancer

Everolimus + Letrozole + Metformin for Endometrial Cancer

Metabolic Pathway Analysis for Pancreatic Cancer

Sebetralstat for Hereditary Angioedema

ARV-471 + Palbociclib for Breast Cancer

Letrozole + Everolimus + TRC105 for Breast Cancer

Epcoritamab for Diffuse Large B-Cell Lymphoma

Niraparib + Trastuzumab for Breast Cancer

ERAS-0015 for Cancer

Related Searches

Top Clinical Trials near Apopka, FL

Top Clinical Trials near Appleton, WI

Top Clinical Trials near Arcadia, CA

Top Clinical Trials near Arkansas City, KS

Top Clinical Trials near Armonk, NY

Top Rhabdomyosarcoma Clinical Trials

Sperm Preparation Techniques for Infertility

Ultrasound Technique for Osteopenia in Premature Infants

Ketorolac for Pain Management

Wild Rice for Cardiovascular Health

Taltz for Laryngostenosis

Combination Therapy for Acute Lymphoblastic Leukemia

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial